Drugs / JNJ-101556143
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06095089 | Nov 2023 → Jun 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06800313 | Feb 2025 → Aug 2028 expected | metastatic prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07832292 | Sep 2026 → May 2029 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-101556143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05818683 ↗ |
| Known as | HLD-0915 | “Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer” NCT06800313 ↗ |
| Modality | Other / unclassified | “an Androgen Receptor-targeted Regulated Induced Proximity Targeting Chimera (RIPTAC™) Therapeutic” NCT07832292 ↗ |
| Route | Oral | “Experimental: Oral JNJ-101556143” NCT06800313 ↗ |